Nisha Shantakumari1, Rasha Ali Eldeeb2, Salwa Abdelzaher Mabrouk Ibrahim3, Jayadevan Sreedharan4, Sufian Otoum5. 1. Asst. Professor, Department of Physiology, Gulf Medical University, Ajman, P.O. Box: 4184, United Arab Emirates. Electronic address: nisha@gmu.ac.ae. 2. Asst. Professor, Department of Physiology, Gulf Medical University, Ajman, P.O. Box: 4184, United Arab Emirates. 3. Department of Internal Medicine, Gulf Medical College Hospital, Ajman, United Arab Emirates. 4. Research Division, Gulf Medical University, Ajman, United Arab Emirates. 5. College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates.
Abstract
INTRODUCTION: Hypertension affects more than a quarter of the global adult population. Studies conducted worldwide suggest an overall small, yet useful, role of omega-3 PUFAs in reducing blood pressure in hypertensive patients. However there is no substantial data in this regard from population based in Middle East and Asia. OBJECTIVES: To determine the effects of (omega-3) PUFA supplementation on the blood pressure of hypertensive patient. To identify if male and female hypertensive patients respond differently to PUFA. To identify if response of hypertensive patients to PUFA varies with the duration of hypertension and co-existence of diabetes/dyslipidemia. MATERIALS AND METHODS: This observational study was conducted among hypertensive patients visiting OPD of the Gulf Medical College Hospital, Ajman, UAE, during the period Jan-Dec 2012. A total of 100 hypertensive patients on treatment with their antihypertensive medications, 50 of whom were taking n-3 PUFA supplementation, were followed up for a period of 3 months. Comparisons were drawn between the BP recordings at the time of enrollment in the study and their follow up values 3 months after enrollment. RESULTS: There was a statistically significant reduction in both the systolic and diastolic blood pressures after 3 months of PUFA therapy. The BP lowering effect of PUFA was more in males. A statistically significant reduction in BP was noted in non-diabetic patients and patients with long standing hypertension. CONCLUSION: Findings of the study suggest that omega-3 PUFA dietary supplements augment the benefits of pharmacotherapy in hypertension.
INTRODUCTION:Hypertension affects more than a quarter of the global adult population. Studies conducted worldwide suggest an overall small, yet useful, role of omega-3 PUFAs in reducing blood pressure in hypertensivepatients. However there is no substantial data in this regard from population based in Middle East and Asia. OBJECTIVES: To determine the effects of (omega-3) PUFA supplementation on the blood pressure of hypertensivepatient. To identify if male and female hypertensivepatients respond differently to PUFA. To identify if response of hypertensivepatients to PUFA varies with the duration of hypertension and co-existence of diabetes/dyslipidemia. MATERIALS AND METHODS: This observational study was conducted among hypertensivepatients visiting OPD of the Gulf Medical College Hospital, Ajman, UAE, during the period Jan-Dec 2012. A total of 100 hypertensivepatients on treatment with their antihypertensive medications, 50 of whom were taking n-3 PUFA supplementation, were followed up for a period of 3 months. Comparisons were drawn between the BP recordings at the time of enrollment in the study and their follow up values 3 months after enrollment. RESULTS: There was a statistically significant reduction in both the systolic and diastolic blood pressures after 3 months of PUFA therapy. The BP lowering effect of PUFA was more in males. A statistically significant reduction in BP was noted in non-diabeticpatients and patients with long standing hypertension. CONCLUSION: Findings of the study suggest that omega-3 PUFA dietary supplements augment the benefits of pharmacotherapy in hypertension.
Authors: Johanna M Geleijnse; Erik J Giltay; Diederick E Grobbee; Adrianus R T Donders; Frans J Kok Journal: J Hypertens Date: 2002-08 Impact factor: 4.844
Authors: Fiona Campbell; Heather O Dickinson; Julia A Critchley; Gary A Ford; Mike Bradburn Journal: Eur J Prev Cardiol Date: 2012-01-30 Impact factor: 7.804